Health
Pfizer Secures Obesity Drug Approval in China
Pfizer has won approval for a GLP-1 obesity drug in China shortly after licensing the shot from Hangzhou-based Sciwind Biosciences.
Key Takeaways
- Pfizer wins China approval for GLP-1 obesity shot licensed from Sciwind
- Enters market where obesity affects over half of Chinese adults
- Licensing approach fast-tracks entry against established rivals Novo and Lilly
DE
DT Editorial AI··via endpoints.news